Shanghai Henlius Biotech, Inc. - PE Ratio

The PE Ratio as of July 2026 (TTM) for Shanghai Henlius Biotech, Inc. (2696.HK) is 23.28

According to Shanghai Henlius Biotech, Inc.’s latest financial reports and current stock price. The company's current PE Ratio is 23.28. This represents a change of -28.78% compared to the average of 32.69 of the last 4 quarters.

Shanghai Henlius Biotech, Inc. (2696.HK) Historical PE Ratio (quarterly & annually)

How has 2696.HK PE Ratio performed in the past?

The mean historical PE Ratio of Shanghai Henlius Biotech, Inc. over the last ten years is -13.97. The current 23.28 PE Ratio has changed -16765.38% with respect to the historical average. Over the past ten years (40 quarters), 2696.HK's PE Ratio was at its highest in in the September 2025 quarter at 43.03. The PE Ratio was at its lowest in in the March 2018 quarter at -75.97.

Shanghai Henlius Biotech, Inc. (2696.HK) PE Ratio by Quarter and Year

Discovering the peaks and valleys of Shanghai Henlius Biotech, Inc. PE Ratio, unveiling quarterly and yearly fluctuations to gain insights into the company’s financial performance and market dynamics, offering valuable data for investors and analysts alike.

Shanghai Henlius Biotech, Inc. (2696.HK) Average PE Ratio

How has 2696.HK PE Ratio performed in the past?

The current PE Ratio of Shanghai Henlius Biotech, Inc. (2696.HK) is greater than its 3-year, greater than its 5-year, and greater than its 10-year historical averages

Shanghai Henlius Biotech, Inc. (2696.HK) PE Ratio vs. Peers

How is 2696.HK’s PE Ratio compared to its peers?

Shanghai Henlius Biotech, Inc.’s PE Ratio is greater than Genscript Biotech Corporation (-6.70), greater than Simcere Pharmaceutical Group Limited (20.53), greater than Shanghai Junshi Biosciences Co., Ltd. (-54.00), less than Asymchem Laboratories (Tianjin) Co., Ltd. (52.09), greater than Livzon Pharmaceutical Group Inc. (13.78), greater than Duality Biotherapeutics, Inc. (-3.34), greater than China Medical System Holdings Limited (17.21), greater than Ascentage Pharma Group International (-8.92), less than RemeGen Co., Ltd. (50.88), greater than Zai Lab Limited (-12.03),

Build a custom stock screener for Shanghai Henlius Biotech, Inc. (2696.HK) and other stocks

One of the best ways to find valuable stocks to invest in is to build a custom made screener in your Excel or Google Sheets spreadsheet. This allows you to compare thousands of companies like Shanghai Henlius Biotech, Inc. using the financials and key metrics that matter to you in a single view.

The easiest way to set this up is to use the Wisesheets add-on and set your spreadsheet like this:

Covering all these metrics from financial, data, dividend data, key metrics and more you can get all the data you want for over 50+ exchanges worldwide.

Get your free trial here.

Shanghai Henlius Biotech, Inc. (2696.HK) and other stocks custom spreadsheet templates

The easiest way to analyze a company like Shanghai Henlius Biotech, Inc. or any others is to create a spreadsheet model that automatically retrieves all of the stock data you need.

Using Wisesheets you can set up a spreadsheet model like this with simple spreadsheet formulas. If you change the ticker you can get all of the data automatically updated for you.

Whether you need live data, historical price data, financials, dividend data, key metrics, analyst estimates, or anything else...Wisesheets has you covered.